The researchers aim to offer the half-hour diagnostic assay for use during neurosurgery to help clinicians pursue the best treatment for patients with gliomas.
The company shared early evidence of the potential of its approach to improve newborn screening for immune disorders, and to offer new tools for other areas like HIV monitoring.
A PCR-based analysis of nearly 700 cases picked up human papillomavirus or human polyomaviruses DNA in a fraction of urothelial bladder carcinoma tumors.
The firm will manufacture its Logix Smart mycobacteria tuberculosis assay at its ISO-certified facility in Utah but will not seek FDA approval at this time, it said.
Using more than 16,000 tick samples submitted by individuals in the mainland US and Puerto Rico, researchers documented tick species and infection by four pathogens.
The Dutch multinational is now on track to introduce a kitted version of the assay, which can be run on standard quantitative PCR equipment, by the end of the year.
The company delivered 4,621 billable tests during Q1, and billable testing volume was the highest in a quarter in Fulgent's history.
PredictImmune's test relies on a 16-marker panel run using quantitative PCR to stratify Crohn's disease and ulcerative colitis patients according to the severity of their illnesses.
Amplidiag CarbaR+MCR detects the main carbapenemase-producing organisms and colistin resistance markers. Novidiag Bacterial GE+ identifies the most common enteric pathogens.
The firms will develop new business opportunities, exchange technical expertise, and integrate their software and hardware systems.
A new paper says an effort to introduce gene drives into mosquitos altered the genetic makeup of the local mosquitos, but the company behind the project says the paper is flawed.
Virginia's Department of Forensic Science is offering attorneys a course on DNA testing, the Virginian-Pilot reports.
Researchers examine changes in the genomes of emmer wheat populations where the climate has warmed, the BBC reports.
In Cell this week: microinjection of CRISPR-Cas9 enables targeted mutations in Anolis, melanoma proteomic profiling, and more.